Home / News / Event #1065324 SEC EDGAR published this disclosure on 2026-09-04. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗ accession 0001385113-26-000002
acquired disposed A
code A
direct or indirect D
form 4
is derivative true
issuer name Protalix BioTherapeutics, Inc.
label Grant or award
Source record & verification Dates, provenance and technical details
Context links are based on the recorded entity type Recorded payload Structured source data
Recorded payload JSON payload as stored after parsing {
"accession": "0001385113-26-000002",
"acquired_disposed": "A",
"code": "A",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": true,
"issuer_name": "Protalix BioTherapeutics, Inc.",
"label": "Grant or award",
"person_name": "Bar-Shalev Amos",
"price": 0,
"role": "Director",
"security": "Stock Options (Right to Buy)",
"shares": 17000,
"shares_owned_after": 17000,
"source_path": "edgar/data/1385113/0001385113-26-000002.txt",
"ticker": "PLX",
"transaction_date": "2026-09-03",
"value": null
}
Evidence-based analysis facts, provenance and explicit model coverage Descriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.